OpenLB
Open Library of Bioscience
Advanced Search
HIV medicine
06, 2023;24 (6): 653-663.

Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?

Geoffroy Liegeon, Jade Ghosn
Author Information
  1. Geoffroy Liegeon: Université Paris Cité, Paris, France.
  2. Jade Ghosn: Université Paris Cité, Paris, France. ORCID
PMID: 36468218 DOI: 10.1111/hiv.13451

Abstract

BACKGROUND: Long-acting injectable cabotegravir (CAB-LA) represents a new additional option for HIV prevention in people at substantial risk of HIV infection that may fill the gaps in pre-exposure prophylaxis (PrEP) uptake, adherence, and retention in users having difficulty with oral PrEP. Data from clinical trials demonstrated that CAB-LA was safe, highly effective, and well-accepted for HIV prevention. However, the occurrence of breakthrough HIV infections despite timely injections, HIV seroconversion timing and patterns, risk of selection and dissemination of resistance-associated mutations to integrase inhibitors, complexity of follow-up, logistical considerations, and its cost effectiveness compared with oral PrEP constitute significant issues for the integration of CAB-LA into clinical routine.
FINDINGS: These concerns need to be addressed before moving forward with large-scale implementation programmes. Pilot and implementation projects are required in the following areas: HIV testing algorithms, patient education, clinic procedures, protocols for switching and discontinuation, efficacy and safety in populations not included in clinical trials, and demedicalization processes. The development of models to increase the uptake of, adherence to, and persistence with and after CAB-LA injections will also be of paramount importance for success. Lessons learned from these projects will increase experience, staff expertise, and organizational and training capacities to support the roll-out of this new agent as part of HIV prevention programmes.
CONCLUSION: CAB-LA has not yet achieved its full potential in HIV prevention, and strong commitment from all stakeholders is required to push CAB-LA as a game-changer in HIV response.

Keywords

HIV pre-exposure prophylaxis long-acting antiretroviral drugs

References

  1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
  2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
  3. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.
  4. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53-60.
  5. World Health Organization. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). Geneva 2015. https://apps.who.int/iris/handle/10665/197906. Accessed December 1, 2022.
  6. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018;5(11):e629-e637.
  7. Grulich AE, Jin F, Bavinton BR, et al. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV. 2021;8(8):e486-e494.
  8. UNAIDS. Pre-exposure prophylaxis use expands, but not fast enough. January 2022. https://www.unaids.org/en/pre-exposure-prophylaxis. Accessed December 1, 2022.
  9. AIDS Vaccine Advocacy Coalition (AVAC). The global PrEP Tracker 2022. https://data.prepwatch.org/. Accessed December 1, 2022.
  10. Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of Care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015;61(10):1590-1597.
  11. Celum C, Baeten J. PrEP for HIV prevention: evidence, global scale-up, and emerging options. Cell Host Microbe. 2020;27(4):502-506.
  12. Centers for Disease Control and Prevention. US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed December 1, 2022.
  13. Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151-1154.
  14. Andrews CD, Yueh YL, Spreen WR, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra4.
  15. Andrews CD, Bernard LS, Poon AY, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. Aids. 2017;31(4):461-467.
  16. Dobard C, Makarova N, Nishiura K, et al. Long-acting cabotegravir protects macaques against repeated penile simian-human immunodeficiency virus exposures. J Infect Dis. 2020;222(3):391-395.
  17. Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331-e340.
  18. Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690.
  19. Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472-e481.
  20. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608.
  21. Landovitz RJ, Donnell D, Ha T, Kallas EG, Magnus M. CAB-LA PrEP keeps advantage over TDF/FTC in 1-year unblinded phase- seven breakthrough infections despite on-time CAB-LA injections. Paper presented at: CROI 2022, February 12-16 and 22-24, 2022.
  22. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789.
  23. Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70(2):319-322.
  24. Delany-Moretlwe SH, Guo X, Hanscom B, et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. Paper presented at:CROI 2022. February 12-16 and 22-24, 2022. Abstract 00700.
  25. Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022;17(3):145-161.
  26. Calabrese SK, Dovidio JF, Tekeste M. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend Planned Parenthood. J Acquir Immune Defic Syndr. 2018;79(1):46-53.
  27. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.
  28. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
  29. Zhang J, Li C, Xu J, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254-e268.
  30. Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther. 2020;37(5):1778-1811.
  31. Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22(2):e25252.
  32. Spinelli MA, Laborde N, Kinley P, et al. Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. J Int AIDS Soc. 2020;23(4):e25472.
  33. Molina JM, Ghosn J, Assoumou L, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554-e562.
  34. Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre-exposure prophylaxis. Drugs. 2019;79(6):609-619.
  35. Chakrapani V, Newman PA, Cameron M, et al. Willingness to use pre-exposure prophylaxis (PrEP) and preferences among men who have sex with men in Mumbai and Chennai, India: a discrete choice experiment. AIDS Behav. 2021;25(10):3074-3084.
  36. Han K, Baker M, Lovern M, et al. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. Br J Clin Pharmacol. 2022;88(10):4607-4622.
  37. Seneviratne HK, Hamlin AN, Li S, et al. Identification of novel UGT1A1 variants including UGT1A1 454C>a through the genotyping of healthy participants of the HPTN 077 study. ACS Pharmacol Transl Sci. 2021;4(1):226-239.
  38. Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;9:jiab152.
  39. Eshleman S, Fogel JM, Halvas EK, CAB-LA-PrEP: early detection of HIV infection may reduce InSTI resistance risk. Paper presented at:CROI 2022. February 12-16 and 22-24, 2022. Abstract 95.
  40. AIDS Vaccine Advocacy Coalition (AVAC). Modelling impact of injectable cabotegravir for PrEP on drug resistance. Andrew Phillips April 2022. https://www.prepwatch.org/wp-content/uploads/2022/04/Modelling-Impact-of-CAB-PrEP-on-Drug-Resistance.pdf. Accessed December 1, 2022.
  41. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization (WHO) Geneva 2021. https://www.who.int/publications/i/item/9789240031593. Accessed December 1, 2022.
  42. Quaife M, Terris-Prestholt F, Eakle R, et al. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21(3):e25064.
  43. van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22(12):e25427.
  44. Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84(2):173-181.
  45. Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224(7):1179-1186.
  46. Neilan AM, Landovitz RJ, Le MH, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175(4):479-489.
  47. Celum CL, Delany-Moretlwe S, Baeten JM, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(Suppl 4):e25298.
  48. Irungu E, Khoza N, Velloza J. Multi-level interventions to promote Oral pre-exposure prophylaxis use among adolescent girls and young women: a review of recent research. Curr HIV/AIDS Rep. 2021;18(6):490-499.
  49. ClinicalTrials.gov. Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants. NCT04484337. https://clinicaltrials.gov/ct2/show/NCT04484337. Accessed December 1, 2022.
  50. Biomedical Prevention Implementation Collaborative (BioPIC). A Collaborative Approach to HIV Prevention Product Introduction. January 2022. https://www.avac.org/sites/default/files/resource-files/BioPIC_strategyBrief_jan2022.pdf. Accessed December 1, 2022.
  51. Coalition to Accelerate Access to Long-Acting PrEP. July 2022. https://www.avac.org/sites/default/files/resource-files/Access-Coalition-Backgrounder_July2022.pdf. Accessed December 1, 2022.
  52. World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva. 2022. https://www.who.int/publications/i/item/9789240054097. Accessed December 1, 2022.

MeSH Term

Humans
HIV Infections
Pyridones
Anti-HIV Agents
Pre-Exposure Prophylaxis

Chemicals

cabotegravir
Pyridones
Anti-HIV Agents
Journal Article Review
Article has an altmetric score of 20

Word Cloud

Created with Highcharts 10.0.0HIVCAB-LApreventionPrEPclinicalLong-actinginjectablecabotegravirnewriskpre-exposureprophylaxisuptakeadherenceoraltrialsinjectionsimplementationprogrammesprojectsrequiredincreasewillgame-changerBACKGROUND:representsadditionaloptionpeoplesubstantialinfectionmayfillgapsretentionusersdifficultyDatademonstratedsafehighlyeffectivewell-acceptedHoweveroccurrencebreakthroughinfectionsdespitetimelyseroconversiontimingpatternsselectiondisseminationresistance-associatedmutationsintegraseinhibitorscomplexityfollow-uplogisticalconsiderationscosteffectivenesscomparedconstitutesignificantissuesintegrationroutineFINDINGS:concernsneedaddressedmovingforwardlarge-scalePilotfollowingareas:testingalgorithmspatienteducationclinicproceduresprotocolsswitchingdiscontinuationefficacysafetypopulationsincludeddemedicalizationprocessesdevelopmentmodelspersistencealsoparamountimportancesuccessLessonslearnedexperiencestaffexpertiseorganizationaltrainingcapacitiessupportroll-outagentpartCONCLUSION:yetachievedfullpotentialstrongcommitmentstakeholderspushresponsePrEP:prevention?HIVlong-actingantiretroviraldrugs

Similar Articles

Cited By